Literature DB >> 19683305

Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging.

Stacy Loeb1, Anna Kettermann, H Ballentine Carter, Luigi Ferrucci, E Jeffrey Metter, Patrick C Walsh.   

Abstract

PURPOSE: According to a 1944 publication by Swyer benign prostatic hyperplasia develops in some men after age 45 with further prostatic growth whereas in other men prostate size remains stable or decreases with advancing age. Although there is an abundance of literature describing prostatic enlargement in association with benign prostatic hyperplasia, less is known about the phenomenon of prostate atrophy.
MATERIALS AND METHODS: In the Baltimore Longitudinal Study of Aging serial pelvic magnetic resonance imaging was performed in men without prostate cancer beginning in 1993. From this population we retrospectively identified 278 men with 2 or more magnetic resonance imaging determined prostate volume measurements to examine differential growth rates in a cohort of community men over time.
RESULTS: Median age was 58 years and median prostate size was 28 cc at study entry. At a median followup of 4.3 years prostate size increased in 61.9% and remained stable or decreased in 38.1% of men. The median rate of volume change was 0.6 cc per year (range -9.9 to 62.1), corresponding to a median growth rate of 2.5% per year (range -29.2 to 176.4%). During followup 64.6% of men with an initial prostate size less than 40 cc had prostate growth compared to only 50.9% of men with an initial prostate size of 40 cc or greater.
CONCLUSIONS: These results suggest that changes in prostate size are highly variable among aging men. Although benign prostatic hyperplasia is common, a considerable proportion of aging men have a stable or decreasing prostate size. Further research is needed to identify the underlying mechanism for such differences in prostate growth.

Entities:  

Mesh:

Year:  2009        PMID: 19683305      PMCID: PMC5003410          DOI: 10.1016/j.juro.2009.06.047

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography.

Authors:  A Rahmouni; A Yang; C M Tempany; T Frenkel; J Epstein; P Walsh; P K Leichner; C Ricci; E Zerhouni
Journal:  J Comput Assist Tomogr       Date:  1992 Nov-Dec       Impact factor: 1.826

2.  Post-natal growth changes in the human prostate.

Authors:  G I Swyer
Journal:  J Anat       Date:  1944-07       Impact factor: 2.610

3.  Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Cynthia J Girman; Michael M Lieber; Michaela E McGree; Steven J Jacobsen
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

4.  The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.

Authors:  C M Tempany; A W Partin; E A Zerhouni; S J Zinreich; P C Walsh
Journal:  Prostate       Date:  1993       Impact factor: 4.104

5.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Authors:  C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

6.  Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Authors:  E James Wright; Junyong Fang; E Jeffrey Metter; Alan W Partin; Patricia Landis; Daniel W Chan; H Ballentine Carter
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

7.  Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.

Authors:  Steven A Kaplan; John D McConnell; Claus G Roehrborn; Alan G Meehan; Michael W Lee; William R Noble; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

8.  Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.

Authors:  Taiji Tsukamoto; Naoya Masumori; Mahbubur Rahman; Martin M Crane
Journal:  Int J Urol       Date:  2007-04       Impact factor: 3.369

9.  Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostatic volume.

Authors:  M al-Rimawi; D J Griffiths; R C Boake; D R Mador; M A Johnson
Journal:  Br J Urol       Date:  1994-11

10.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

View more
  35 in total

1.  Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study.

Authors:  Si-Hui Li; Qun-Fang Yang; Pei-Yuan Zuo; Yu-Wei Liu; Yu-Hua Liao; Cheng-Yun Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

2.  Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue.

Authors:  Jai Hyun Chung; Ji Hyeong Yu; Luck Hee Sung; Chung Hee Noh; Jae Yong Chung
Journal:  Korean J Urol       Date:  2012-02-20

3.  Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.

Authors:  Zongwei Wang; Libing Hu; Keyan Salari; Seth K Bechis; Rongbin Ge; Shulin Wu; Cyrus Rassoulian; Jonathan Pham; Chin-Lee Wu; Shahin Tabatabaei; Douglas W Strand; Aria F Olumi
Journal:  J Pathol       Date:  2017-12       Impact factor: 7.996

4.  Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients.

Authors:  Baris Turkbey; Robert Huang; Srinivas Vourganti; Hari Trivedi; Marcelino Bernardo; Pingkun Yan; Compton Benjamin; Peter A Pinto; Peter L Choyke
Journal:  BJU Int       Date:  2012-09-14       Impact factor: 5.588

5.  Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; George G Klee; Michael M Lieber; Steven J Jacobsen
Journal:  Am J Epidemiol       Date:  2011-03-02       Impact factor: 4.897

6.  Typology of intravesical prostatic protrusions, or so-called median lobes, in middle-aged and older men.

Authors:  Marie Audouin; Alexis Girshovich; Olivier Cussenot; Raphaele Renard-Penna
Journal:  Surg Radiol Anat       Date:  2018-03-13       Impact factor: 1.246

Review 7.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

8.  Relationship between age and prostate size.

Authors:  Shi-Jun Zhang; Hai-Ning Qian; Yan Zhao; Kai Sun; Hui-Qing Wang; Guo-Qing Liang; Feng-Hua Li; Zheng Li
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

Review 9.  Prostatic Urethral Lift Versus Transurethral Resection of the Prostate (TURP).

Authors:  Giuseppe Magistro; Christian G Stief; Christian Gratzke
Journal:  Curr Urol Rep       Date:  2017-08-29       Impact factor: 3.092

10.  Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?

Authors:  Zongwei Wang; Aria F Olumi
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.